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Background: The sigma-1 receptor (σ1R), an endoplasmic reticulum chaperone protein, is widely distributed and
regulates numerous intracellular processes in neurons. Nerve injury alters the structure and function of axotomized
dorsal root ganglion (DRG) neurons, contributing to the development of pain. The σ1R is enriched in the spinal
cord and modulates pain after peripheral nerve injury. However, σ1R expression in the DRG has not been studied.
We therefore characterized σ1R expression in DRGs at baseline and following spinal nerve ligation (SNL) in rats.
Results: Immunohistochemical (IHC) studies in DRG sections show σ1R in both neuronal somata and satellite glial
cells. The punctate distribution of σ1R in the neuronal cytoplasm suggests expression in the endoplasmic reticulum.
When classified by neuronal size, large neurons (>1300 μm) showed higher levels of σ1R staining than other groups
(700-1300 μm, <700 μm). Comparing σ1R expression in neuronal groups characterized by expression of calcitonin
gene-related peptide (CGRP), isolectin-B4 (IB4) and neurofilament-200 (NF-200), we found σ1R expression in all three
neuronal subpopulations, with highest levels of σ1R expression in the NF-200 group. After SNL, lysates from L5
DRGs that contains axotomized neurons showed decreased σ1R protein but unaffected transcript level, compared
with Control DRGs. IHC images also showed decreased σ1R protein expression, in SNL L5 DRGs, and to a lesser
extent in the neighboring SNL L4 DRGs. Neurons labeled by CGRP and NF-200 showed decreased σ1R expression in
L5 and, to a lesser extent, L4 DRGs. In IB4-labeled neurons, σ1R expression decreased only in axotomized L5 DRGs.
Satellite cells also showed decreased σ1R expression in L5 DRGs after SNL.
Conclusions: Our data show that σ1R is present in both sensory neurons and satellite cells in rat DRGs. Expression
of σ1R is down-regulated in axotomized neurons as well as in their accompanying satellite glial cells, while
neighboring uninjured neurons show a lesser down-regulation. Therefore, elevated σ1R expression in neuropathic
pain is not an explanation for pain relief after σ1R blockade. This implies that increased levels of endogenous σ1R
agonists may play a role, and diminished neuroprotection from loss of glial σ1R may be a contributing factor.
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Dorsal root ganglionBackground
Sigma-1 receptor (σ1R), a non-opioid receptor residing at
the mitochondria-associated endoplasmic reticulum (ER)
membrane [1], is widely distributed in various tissues
including heart, liver, immune cells, as well as the nervous
system [2-6]. Cellular functions are regulated by σ1R bind-
ing through a wide range of signaling pathways including
protein kinases, ion channels, and transcription factors
[7-10]. The σ1Rs are abundant in the central nervous* Correspondence: hwu@mcw.edu
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reproduction in any medium, provided the orsystem, where they may contribute to psychostimulant ad-
diction [11,12], neurodegenerative disorders [13],
neuroinflammation [14] and neuroprotection [15,16]. We
have previously demonstrated that the σ1R mediates
(+)-morphine induced anti-analgesia through actions at
both supraspinal and spinal sites [17-19]. Other reports
show that opioid ligand-induced antinociception is attenu-
ated by σ1R agonists and potentiated by σ1R antagonists
[20-23]. Further, σ1R antagonists effectively attenuate pain-
ful behavior in neuropathic and inflammatory pain models
[24-29]. Although much remains to be learned about the
role of the σ1R in health and disease, these various findings
together point toward a significant role in pain modulation.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and functional changes in peripheral, spinal cord, and
supraspinal sites that contribute to long-term neuro-
pathic pain [30-34]. Our previous findings demonstrate
that injured sensory neurons have diminished voltage-
gated Ca2+ influx and reduced intracellular Ca2+ stores
[35-37]. These features are of particular relevance to a
potential role of σ1R in neuropathic pain since store de-
pletion activates σ1R [1,38], and σ1R activation reduces
ICa in other types of neurons [6,39]. Furthermore, the
dorsal root ganglion (DRG), site of the somata of periph-
eral sensory neurons, generates neurosteroids that are
σ1R ligands [40-42]. Although this evidence suggests
that peripheral sensory neuron σ1Rs may contribute to
the complex of changes that result in chronic neuro-
pathic pain, expression of σ1Rs in this neuronal popula-
tion has not been explored. In the present study, we
therefore characterize the expression and distribution of
σ1R in sensory neurons. Since elevated σ1R expression
could contribute to the generation of neuropathic pain,
we also examine the influence of painful nerve injury.
We found that σ1Rs are present in both neurons and
satellite glial cells (SGCs) in the DRG, and that σ1Rs are
down-regulated after peripheral nerve injury.
Results
A total of 31 rats were used in the present study, of which
16 were Control animals and 15 had painful neuropathy in-
duced by spinal nerve ligation (SNL). All SNL animals
demonstrated hyperalgesic responses, whereas no animals
in the Control group did. The frequency of hyperalgesia re-
sponses from noxious punctate mechanical stimulation in
SNL rats (32 ± 3%) was greater than in control rats (0 ± 0%;
P < 0.001). All SNL animals used in this study had greater
than 20% hyperalgesia responses (at least 6 responses to a
total of 30 pin stimulations from 3 sensory test sessions).
Within a single testing session, we see no pattern of accu-
mulating sensitivity or accommodation to the stimuli. The
anatomical accuracy of the SNL surgery was confirmed at
the time of tissue harvest in all SNL animals.
Both DRG neurons and satellite cells exhibit σ1R
immunofluorescence
We first used immunohistochemical (IHC) methods to
identify if σ1R protein is present in the DRG. Fluorescent
images of σ1R staining in DRG sections revealed the pres-
ence of σ1R in neuronal somata in a punctate distribution
in the cytoplasm (Figure 1A,B), consistent with its location
in the ER [1,43]. Double staining for σ1R combined with
NeuN, a neuron-specific marker, revealed expression of
σ1R in all neurons (Figure 1A). Using glutamine synthetase
[44,45] as a marker for astrocyte-like SGCs [46], sections
also demonstrated expression of σ1R in SGCs (Figure 1B).
This finding is consistent with prior reports of the presenceof σ1R in glial cells such as astrocytes and Schwann cells
[3,47]. When classified into different neuronal subpopula-
tions by size, large neurons comparatively higher levels of
σ1R expression (Figure 1C). This suggests that there may
be neuron subtype-specific expression of σ1R. Accordingly,
we compared σ1R expression in neuronal groups character-
ized by expression of CGRP, a marker of small unmyelin-
ated peptidergic primary sensory neurons, by binding of
IB4, a marker of small unmyelinated non-peptidergic sen-
sory neurons, and by expression of NF200, a marker of
large, myelinated neurons [48,49]. This analysis confirmed
comparatively higher σ1R expression in the NF200 group
(Figure 1D, E), consistent with their larger size.
Effect of injury on σ1R Expression in DRG
Transcripts for σ1R have previously been found in neuronal
tissues [50,51], but their presence has not been examined in
peripheral sensory neurons. We identified σ1R at the tran-
script level in DRG lysates (Figure 2A), confirming the IHC
findings of its expression there. As an initial examination of
the effect of injury on sensory neuron σ1R expression, we
also examined lysates from animals that developed painful
neuropathy following SNL. Examination of transcript level
(Figure 2A) did not show any significant changes. However,
Western immunoblotting of lysates using a commercially
available antibody (Invitogen) demonstrated significantly
down-regulated σ1R protein expression in SNL L5 DRGs
compared to Control, while neighboring SNL L4 DRGs
showed an intermediate level of σ1R protein expression
(Figure 2B,C). These Western findings were duplicated
using another σ1R antibody (gift from Drs. T. P. Su and T.
Hayashi at NIDA; data not shown).
Effect of injury on σ1R immunofluorescence in
subpopulations of DRG neurons
To further evaluate the effect of injury on σ1R expres-
sion, we quantified IHC images from DRG sections fol-
lowing SNL (Figure 3A). Immunofluorescent intensity of
σ1R was attenuated in both axotomized SNL L5 DRGs
and, to a lesser extent, in the neighboring SNL L4 DRG
(Figure 3B). The finding is consistent with our Western
blotting result (Figure 2), in which σ1R protein expres-
sion decreased more in SNL L5 than in SNL L4 DRGs.
This pattern was found in small and medium size groups
(Figure 3C), although large neurons failed to show an ef-
fect on the SNL L5 group, which were few in number.
For the neuronal subpopulation labeled with CGRP
(Figure 4A), we found that σ1R expression decreased
not only in SNL L5 but also in neighboring uninjured L4
DRG neurons, compared to Control (Figure 4B). IB4
showed plasma membrane and perinuclear staining
(Figure 5A), consistent with a previous description [52].
Double staining for σ1R with IB4 revealed that expres-







































Figure 1 σ1 Receptor (σ1R) in various Control dorsal root ganglion (DRG) cell populations. (A) Staining for σ1R was uniformly distributed
within cytoplasmic areas of cells identified as neuronal profiles through co-staining with NeuN. No specific σ1R staining was found in neuronal
nuclei. (B) σ1R was also found in cellular components identified as satellite glial cells by their expression of glutamine synthase (GS). Identically
placed arrows in the left and middle panels indicate cellular areas clearly identifiable as satellite glial cell cytoplasm that expresses σ1R.
(C) Classification of control DRG neurons by size (<700, 700-1300 and >1300 μm3) showed greater σ1R intensity (arbitrary units, recorded using
standardized image acquisition) in large neurons compared to others. (D) σ1Rs expression is compared in neuronal subtypes identified by their
expression of calcitonin-gene related peptide (CGRP), isolectin B-4 (IB4), and neurofilament-200 (NF-200). (E) Higher fluorescent intensity for σ1Rs
was found in the subpopulation of control neurons expressing NF-200. Mean ± SEM; number in bars represents the sample size; *p < 0.05, **
p < 0.01, ***p < 0.001.
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http://www.molecularpain.com/content/9/1/47L4 neurons (Figure 5B). Double staining for σ1R with
NF200 (Figure 6A) showed decreased σ1R expression in
both L4 and L5 DRGs after SNL, compared to Control
(Figure 6B).Effect of injury on σ1R immunofluorescence in DRG
satellite glial cells
Using immunostaining of glutamine synthetase to de-
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Figure 2 Effect of injury on σ1 Receptor (σ1R) expression in dorsal root ganglia (DRG). (A) Transcript measured by quantitative real time
PCR showed no significant differences in σ1R level after spinal nerve ligation (SNL) in both the axotomized 5th lumbar (L5) dorsal root ganglion
and the adjacent 4th lumbar (L4) ganglion, compared to control (C) ganglia. (B) Protein measurement by Western blot showed a dominant band
at the expected molecular weight that was decreased in both L4 and L5 ganglia after SNL compared to control DRGs. β-Tubulin 1 (β-Tub) was
used as loading control. (C) Summary data of Western blot showed a significant decrease of σ1R protein expression in axotomized L5 DRG. Both
graphs show Median and interquartile range for fold difference from normalized controls; numbers in bars represents the sample size; **p < 0.01.
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cells of the L5 DRG following SNL (Figure 7A,B).
Discussion
Several key findings emerge from our examination of
σ1R expression in control and injured sensory neurons.A


















Figure 3 Effect of injury on σ1 receptor (σ1R) expression in sensory n
intensity were found in both spinal nerve ligation (SNL) 4th lumbar (L4) an
(B) Summary data showed decrease of intensity of staining in SNL L4 and
by neuronal size (<700, 700-1300 and >1300 μm3), SNL L4 DRG neurons sh
image acquisition) than Control in all three size groups, and SNL L5 neuron
than Controls. The data for Control groups are the same as shown in FigurWe demonstrated that σ1Rs were present in both sen-
sory neurons and SGCs. In line with previous reports
[5,43,53,54], we found that σ1Rs are dispersed through-
out the cytoplasm of DRG neurons in all size and histo-
chemical subgroups. Expression of the σ1R protein






















eurons. (A) Decreases of σ1 receptor (σ1R) immunofluorescence
d 5th lumbar (L5) neurons compared with that in Control animals.
L5 neurons. Number in bars represents the n for neurons. (C) Classified
owed lower σ1R intensity (arbitrary units, recorded using standardized
s in the small and medium size groups showed lower σ1R intensity
e 1C. Mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.

















Figure 4 Effect of injury on σ1 receptor (σ1R) expression in sensory neurons identified by calcitonin-gene related peptide (CGRP)
staining. (A) Staining of σ1R was distributed within cytoplasmic areas of all CGRP co-expressing neurons. σ1R immunofluorescence intensity was
decreased in both spinal nerve ligation (SNL) 4th lumbar (L4) and 5th lumbar (L5) neurons compared with Control. (B) Summary data showed
decrease of intensity of σ1R staining in CGRP-positive SNL L4 and L5 neurons. Mean ± SEM; number in bars represents the sample size;
***p < 0.001.
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all neuronal subpopulations. These observations confirm
the presence of σ1R in the DRG, which was previously
suspected on the basis of ligand binding studies [53,55].
Furthermore, our findings also support a role for pri-
mary sensory neuron σ1Rs in pain generation after
injury.
In the present study, we determined the average σ1R
expression in relevant DRG neuronal subgroups and theeffect of SNL. In prior IHC analysis by Hammond et al.
[52], it was shown that SNL also affects the number of
neurons in these subgroup populations. Specifically,
axotomy decreases the number of neurons in both the
CGRP and IB4 subgroups in L5 DRGs, whereas SNL L4
neurons are unaffected [52]. These populations recover
over the ensuing 20 weeks, and partial recovery occurs
by the 3-week time point that we used in the present
study. This downward shift in neuron population size,


















Figure 5 Effect of injury on σ1 receptor (σ1R) expression in sensory neurons identified by IB4 staining. (A) Staining of σ1R was
distributed within cytoplasmic areas of all IB4 co-expressing neurons. σ1R immunofluorescence intensity was decreased in spinal nerve ligation
(SNL) 5th lumbar (L5) neurons compared with Control. (B) Summary data showed decrease of intensity of σ1R staining in IB4-positive SNL L5
neurons. Mean ± SEM; number in bars represents the sample size; ***p < 0.001.
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expression per neuron, could amplify the functional ef-
fect of depression of σ1R in neurons of the CGRP and
IB4 subgroups (typically small nociceptors). Our data do
not provide any insight into the cause of depressed σ1R
levels after nerve injury. However, it is possible that ac-
celerated axonal transport of σ1R from the sensory
neuron soma may account for receptor depletion there.
Specifically, σ1R bound to the ER membrane is activated
by ER stress, such as occurs with ER Ca2+ depletion thatfollows nerve injury [35]. Thereupon, σ1R is relocated to
targeted cell compartments [38,56,57], which may in-
clude non-somatic regions.
We found that σ1R expression was depressed in SNL
L4 DRGs, although not to the same extent as in
axotomized L5 neurons and not in the IB4 population. It
has been shown that L5 axotomy results in changes of a
variety of signaling peptides and cellular function in the
uninjured L4 DRG neurons [58,59]. In common with
these phenotypic shifts, decreased σ1R expression in


















Figure 6 Effect of injury on σ1 receptor (σ1R) expression in sensory neurons identified by neurofilament-200 (NF-200) staining.
(A) Staining of σ1R was distributed within cytoplasmic areas of all NF-200 co-expressing neurons. σ1R immunofluorescence intensity was
decreased in both spinal nerve ligation (SNL) 4th lumbar (L4) and 5th lumbar (L5) neurons compared with Control. (B) Summary data showed
decrease of intensity of σ1R staining in IB4-positive SNL L4 and L5 neurons. Mean ± SEM; number in bars represents the sample size; **p < 0.01,
***p < 0.001.
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cesses triggered by the degeneration of axotomized distal
segments of L5 neurons within the distal sciatic nerve
[60-62].
We must consider what our present findings may indi-
cate for the role of σ1R in pain processing. It is clear
that σ1R activation potentiates nociceptive responses
under both baseline conditions and in the setting of fa-
cilitated pain models [20,22,24,63,64]. In the specificsetting of nerve injury, responses to mechanical and
thermal stimuli are potentiated by σ1R agonists and at-
tenuated by σ1R antagonists or genetic elimination of
σ1R [65]. Implicated signaling pathways include nitric
oxide, PKC, PKA, and NMDA receptor in the spinal
cord [24-29]. One possible explanation of these events
would be injury-induced overexpression of σ1R. Our re-
sults, however, clearly indicate that σ1R expression is
down-regulated in primary sensory neurons in the
















Figure 7 Effect of injury on σ1 receptor (σ1R) expression in satellite glial cells identified by glutamine synthase (GS) staining.
(A) Intensity of σ1R was decreased in cytoplasmic areas of satellite glial cells in 5th lumbar (L5) DRGs after spinal nerve ligation. (B) Summary data
for average intensity in satellite glial areas showed decrease of intensity of σ1R staining in GS-positive glial cells in SNL L5 dorsal root ganglia.
Mean ± SEM; number in bars represents the section sample size; **p < 0.01.
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ine earlier time points. In contrast to our DRG findings,
spinal cord dorsal horn homogenates show elevated σ1R
protein expression early (3 days) after sciatic nerve in-
jury [25], but since expression returns to control level by
day 7, a shift in dorsal horn σ1R levels is also unlikely to
contribute chronic neuropathic pain. It therefore appears
that the σ1R activation and blockade influence pain sig-
naling either through the relatively unaffected L4 neu-
rons, or that the σ1R remaining in the axotomizedpopulation is sufficient for these modulators to alter pain
generation. Likewise, there may be a pathogenic role for
σ1R in neuropathic pain if levels of endogenous
neurosteroid agonists such as dehydroepiandrosterone
[66] and pregnenolone increase sufficiently to produce
elevated σ1R effects despite lowered σ1R expression.
Recent studies have shown that σ1Rs are present in
oligodendroglia and astrocytes in the CNS [4,47,67,68]
and in Schwann cells of the sciatic nerve [3]. Since SGCs
in the DRG play a similar role as astrocytes in CNS [46]
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Schwann cells [69], our finding of σ1R in SGCs is con-
sistent with these previous reports. After ischemic brain
injury, σ1Rs are upregulated in reactive astrocytes as
well as neurons [67], which reduces glutamate accumu-
lation and inhibits interleukin-1β expression and micro-
glial migration to abate ischemia-induced inflammatory
reaction [70,71] (reviewed in [7]). Our data show that
peripheral nerve injury differs from ischemic brain injury
since σ1R decreases in the ganglia in which axotomized
neurons reside. This may deprive such neurons of the
evident protective effects of σ1R modulation of inflam-
matory processes and indirectly contribute to the gener-
ation of chronic pain after nerve injury.
Conclusions
Our findings indicate that σ1Rs are present in sensory
neurons, thus supporting these neurons as a possible site
of action in enhancing pain after intrathecal σ1R activa-
tion and reducing pain with σ1R blockade [25,27,72].
After peripheral nerve injury, σ1R expression is de-
creased in axotomized L5 and to a lesser extent in
neighboring L4 DRG neurons in all tested neuronal sub-
populations, which eliminates injury-induced change of
neuronal receptor expression as a pathogenic mechan-
ism. Overexpression of endogenous σ1R agonists may
account for sensitivity of neuropathic pain to σ1R block-
ade, and loss of glial σ1R may be a contributing factor.
Methods
Animals
All methods and use of animals were approved by the
Medical College of Wisconsin Institutional Animal Care
and Use Committee. Male Sprague-Dawley rats (Taconic
Farms Inc., Hudson, NY) were housed individually in a
room maintained at 22 ± 0.5°C and constant humidity
(60 ± 15%) with an alternating 12 hr light-dark cycle.
Food and water were available ad libitum throughout
the experiments.
Injury model
Rats weighing 150 to 180 g were subjected to SNL modified
from the original technique [73]. Specifically, rats were
anesthetized with 2% isoflurane in oxygen and the right
paravertebral region was exposed. The L6 transverse
process was removed, after which the L5 and L6 spinal
nerves were ligated with 6-0 silk suture and transected dis-
tal to the ligature. To minimize non-neural injury, no
muscle was removed, muscles and intertransverse fascia
were incised only at the site of the two ligations, and articu-
lar processes were not removed. The muscular fascia was
closed with 4-0 resorbable polyglactin sutures and the skin
closed with staples. Control animals received skin incision
and closure only. After surgery, rats were returned to theircages and kept under normal housing conditions with ac-
cess to pellet food and water ad lib.
Sensory testing
We measured the incidence of a pattern of hyperalgesic
behavior that we have previously documented to be as-
sociated with conditioned place avoidance [74,75].
Briefly, on day 10, 12, and 17 after surgery, right plantar
skin was touched (10 stimuli/session) with a 22G spinal
needle with adequate pressure to indent but not pene-
trate the skin. Control animals respond with only a brief
reflexive withdrawal, whereas rats subjected to SNL may
display a complex hyperalgesia response that includes
licking, chewing, grooming and sustained elevation of
the paw, which peaks in frequency by day 17. Because of
day-to-day variability in individual rat responses, the
average frequency of hyperalgesia responses over the 3
testing days was tabulated for each rat. After SNL, only
rats that displayed a hyperalgesia-type response after at
least 20% of stimuli were used further in this study.
Quantitative real-time PCR analysis
Total RNA was isolated from the homogenized L4 and
L5 DRG of control animals (n = 6), and separately from
the L4 and L5 DRGs of SNL rats (n = 6) harvested 21 days
after surgery, following the manufacturer’s (Invitrogen,
Carlsbad, CA) instructions using Trizol reagent (from
aqueous phase). After DNase treatment, cDNA was syn-
thesized from amounts of RNA that were standardized
for each experiment ranging from 152 to 232 ng for dif-
ferent experiments, using random hexamer primers
(Superscript III first strand synthesis kit; Invitrogen,
Grand Islands, NY). Quantitative real time PCR (qPCR)
analysis was carried out using IQ Syber Green supermix
(Biorad Laboratories, Hercules, CA) and specific primers
to quantify the cDNA levels of the σ1R genes (for-
ward primer (FP), 5’-CCTGCTGGCATTCGGGGCTC-3’;
reverse primer (RP), 5’-TCACAGCTGCAGGCGAACG
G-3’; NCBI reference sequence, NM_030996.1). A pre-
liminary gel showed that PCR products had the expected
molecular weight and a melting curve was run in each
sample to confirm single product in every run (data not
shown). Normalization was carried out using the geomet-
ric mean of two reference genes, glyceraldehyde 3-
phohphate dehydrogenase (GAPDH; FP, 5′-AGACAGCC
GCATCTTCTTGT-3′; RP, 5′-TGATGGCAACAATGT
CCACT-3′) and mitogen-activated protein kinase 6
(MAPK6; FP, 5′-TAAAGCCATTGACATGTGGG-3′; RP,
5′-TCGTGCACAACAGGGATAGA-3′), which were cho-
sen for their stability in the context of SNL injury [76].
For each sample, two inter-run determinations were av-
eraged and the fold differences in expression (SNL L4,
and SNL L5 DRG) were compared to that of the Control
samples using the comparative CT method. Statistical
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MAPK6/GAPDH, was performed using Kruskal-Wallis
test (p = 0.073) with Post hoc by Dunn’s test. Graphs were
plotted using 2-ΔΔCT values for representation of σ1R
gene expressions in different groups.
Western blot analysis
Total protein was isolated from individual L4 and L5 DRGs
of Control animals, and separately from L4 and L5 DRGs
of SNL animals. Harvested ganglia were homogenized in
150 μl of RIPA lysis buffer containing protease inhibitors
(Roche Diagnostics, Indianapolis, IN) and phosphatase in-
hibitors (Thermo Scientific, Rockford, IL), and incubated
on ice for 30 minutes. Lysates were spun down at
14000 rpm for 10 min at 4°C. The supernatant was used
for protein estimation using Pierce bicinchoninic acid pro-
tein assay kit (Thermo Scientific, Rockford, IL). Equal
amounts of protein (30 μg) were separated on 4-15% so-
dium dodecyl sulphate polyacrylamide gel electrophoresis
gel (SDS-PAGE; Bio-Rad, Hercules, CA) and transferred
onto a polyvinylidene fluoride membrane. After blocking
with 5% milk in TBS-T (Tris-buffered saline plus 0.1%
Tween 20), blots were sequentially probed overnight at 4°C
with one of two anti-σ1R rabbit polyclonal antibodies, ei-
ther a commercial product (1:500, Invitrogen, Camarillo,
CA, catalog number 42-3300; Lot No. 797152A, polyclonal
affinity-purified antibody raised against a synthetic peptide
derived from the C-terminus region (amino acid 139-155)
of the rat σ1R), or another that was a kind gift from Drs. Su
and Hayashi of NIDA (1:1000, Lot No. 6405, polyclonal
affinity-purified antibody raised against amino acid 52-69
from the C-terminus of rat σ1R) [6,77]. Loading control
was used anti-β-tubulin I mouse monoclonal antibody
(1:5000, Sigma-Aldrich, St. Louis, MO, catalog number
T7816, Lot No. 088 K4795, monoclonal antibody raised
against a synthetic peptide corresponding to the C-
terminus sequence of β-tubulin isotype I, conjugated to
BSA) [45]. Three 15 min washes in TBS-T followed be-
fore probing with secondary antibody of horseradish
peroxidase-conjugated goat anti-rabbit antibody (1:2000,
Pierce, Rockford, IL). Enhanced chemiluminescence (ECL
plus; Amersham, Piscataway, NJ) was used to detect protein
bands. Western blot restore stripping buffer (Thermo Sci-
entific, Rockford, IL) was used to strip antibodies from the
membrane. The bands obtained were quantified using
ImageJ (U.S. National Institutes of Health, Bethesda, MD)
program, and β-tubulin I was used to normalize the protein
loading. The normalized values (to β-tubulin I) of Control,
SNL L4 and SNL L5 isoform were used for the statistical
analysis. Although the antibody from NIDA showed a
strong expression band at the expected molecular weight
(25 kDa), the blot also showed non-specific bands as well
(data not shown). The more selective Invitrogen antibody
was used for immunohistochemistry.Immunohistochemistry
Twenty-one days post-surgery, the Control, SNL L4 and
SNL L5 DRGs were harvested and cryoprotected in 4%
paraformaldehyde with 15% sucrose in 0.1 M PBS for 1 h,
followed by incubation in 30% sucrose 0.1 M PBS overnight
[49]. Tissues embedded in Tissue-Tek optimal cutting
temperature compound (Ted Pella, Inc., Redding, CA) were
sectioned (10 μm) with a Leica cryostat (Jung CM 1800;
Vienna, Austria), plated onto subbed slides (Superfrost Plus
Gold; Fisher Scientific, Pittsburgh, PA), and post-fixed in
4% paraformaldehyde with 4% sucrose for 10 min. After
blocking with 10% normal goat serum for 1 h at room
temperature, the tissue was incubated overnight with anti-
σ1R rabbit polyclonal antibody (1:100, Invitrogen, same
antibody used Western) [77]. After four washes with PBST,
sections were incubated with Alexa Fluor 568 Goat anti-
rabbit antibody (1:500; Invitrogen, Camarillo, CA) for 2 h.
To determine co-localization of σ1R with the neuron-
specific nuclear protein (NeuN), neurofilament 200 (NF-
200), CGRP, and glutamine synthetase, the sections were
washed four times with PBST followed by incubated with
anti-NeuN mouse monoclonal antibody (1:100, Millipore,
Billerica, MA, catalog number MAB377, Lot No.
LV1616015, monoclonal antibody raised against purified
cell nuclei from mouse brain) [45], anti-NF-200 mouse
monoclonal antibody (1:1000, Abcam, Cambridge, UK,
catalog number ab28029, monoclonal antibody raised
against a non phosphorylated epitope from 200kD
Neurofilament Heavy of most mammalian species) [49],
anti-CGRP mouse polyclonal antibody (1:50, Santa Cruz
Biotechnology, Santa Cruz, CA, catalog number SC-28920,
Lot No. H1407, epitope corresponding to amino acid 81-
128 mapping at the C-terminus of CGRP of human origin)
[49], or anti-glutamine synthetase rabbit polyclonal anti-
body (1:500, Santa Cruz Biotechnology, Santa Cruz, CA,
catalog number SC-6640, Lot No. H1407, polyclonal affinity
purified antibody raised against a peptide mapping at the
C-terminus of glutamine synthetase of human origin) [45]
for 2 h. Following four washes with PBST, sections were in-
cubated with Alexa Fluor 488 goat anti-mouse antibody or
Alexa Fluor 488 goat anti-rabbit antibody (1:1000; Molecu-
lar Probes, Camarillo, CA) for 1 h. To determine co-
localization of σ1R with IB4, sections were incubated with
Alexa Fluor 488 conjugate IB4 (1:50, Invitrogen, Camarillo,
CA, catalog number I21411, Lot No. 743633,) [78] after
four washes with PBST. Sections were washed four times
with PBSTand covered with Prolong Gold Antifade mount-
ing medium (Invitrogen, Camarillo, CA). Sections were ex-
amined by confocal microscopy. The expression level of
σ1R protein was represented by the image intensity that
was captured using standardized camera parameters
(Metamorph, Downingtown, PA), and cell area was deter-
mined by outlining the neuronal profile by excluding its nu-
cleus. A neuron was considered positive when intensity in
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sections incubated without targeting primary antibody. At
least 3 sections from each DRG were randomly chosen for
fluorescence intensity measurement, except in a case of
SNL L5 DRG with σ1R/CGRP double staining, for which 2
sections were evaluated. The fluorescence intensity of all
cells in the section was quantified. The individual who mea-
sured the fluorescence intensity was not completely blinded
to the treatment due to obvious markers of axotomy such
as eccentric location of the nucleus. Average fluorescence
intensity of neurons was measured in traced cytoplasmic
areas of interest after subtracting background fluorescence
[49,79]. Satellite glial cell σ1R average intensity was derived
by creating a mask from a thresholded image of glutamine
synthetase immunofluorescence to isolate areas of interest
in the image of σ1R immunofluorescence using Photoshop
(Adobe Systems Inc., New York City, NY).
Statistical analysis
Prism (version 6.1, GraphPad Software, Inc., San Diego,
CA) was used to perform paired or unpaired Student’s t-
test or one-way ANOVA. Data were derived from at least 3
DRGs for every group. Non-parametric Kruskal-Wallis test
with Post hoc by Dunn’s test was used for analyzing the in-
fluence of injury on σ1R in qPCR and Western immunoblot
experiments. In IHC experiments, main effects identified by
ANOVA were further analyzed by Tukey’s test (for compar-
isons between all groups) to compare relevant means. Data
are reported as median with interquartile range for qPCR
and Western immunoblot experiments, and as mean ±
SEM for IHC experiments. A P value less than 0.05 was
considered significant.
Abbreviations
SNL: Spinal nerve ligation; CNS: Central nervous system; DRG: Dorsal root
ganglion; SGC: Satellite glial cells; σ1R: Sigma-1 receptor; IB4: Isolectin-4;
CGRP: Calcitonin gene-related protein; NeuN: Neuron-specific nuclear
protein; NF-200: Neurofilament 200; IHC: Immunohistochemical.
Competing interests
The authors declare that they have on competing interests.
Authors’ contributions
BML designed quantitative real time PCR experiment, acquired, analyzed and
interpreted data and also contributed to western blotting and IHC studies;
DM contributed to confocal microscope study in analyzing and interpreted
IHC data; VZ contributed to IHC studies; QBT contributed to western blotting
and IHC study designs; QH participated in interpretation of the data, and
revising the manuscript; HEW contributed to the conception and design of
the studies, interpretation of the data, writing and revising the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The study was supported by National Institutes of Health Grant DA-K01
-024751 (to H.-E. W.) and NS-R01-42150 (to Q.H. H.).
Author details
1Department of Anesthesiology, Medical College of Wisconsin, 8701
Watertown Plank Road, Milwaukee, WI 53226, USA. 2Zablocki Veterans
Administration Medical Center, Milwaukee, WI, USA.Received: 27 June 2013 Accepted: 7 September 2013
Published: 10 September 2013References
1. Hayashi T, Su TP: Sigma-1 receptor chaperones at the ER-mitochondrion
interface regulate Ca(2+) signaling and cell survival. Cell 2007,
131:596–610.
2. Matsumoto RR: σ Receptors: historical perspective and background. In
Sigma Receptors. 1st edition. Edited by Matsumoto RR, Bowen WD, Su T-P.
New York, NY: Springer; 2007:1–23.
3. Palacios G, Muro A, Verdu E, Pumarola M, Vela JM: Immunohistochemical
localization of the sigma1 receptor in Schwann cells of rat sciatic nerve.
Brain Res 2004, 1007:65–70.
4. Palacios G, Muro A, Vela JM, Molina-Holgado E, Guitart X, Ovalle S,
Zamanillo D: Immunohistochemical localization of the sigma1-receptor in
oligodendrocytes in the rat central nervous system. Brain Res 2003,
961:92–99.
5. Alonso G, Phan V, Guillemain I, Saunier M, Legrand A, Anoal M, Maurice T:
Immunocytochemical localization of the sigma(1) receptor in the adult
rat central nervous system. Neuroscience 2000, 97:155–170.
6. Tchedre KT, Huang RQ, Dibas A, Krishnamoorthy RR, Dillon GH, Yorio T:
Sigma-1 receptor regulation of voltage-gated calcium channels involves
a direct interaction between sigma-1 receptors and the voltage-gated L-
type calcium channel. Invest Ophthalmol Vis Sci 2008, 49:4993–5002.
7. Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP: Targeting ligand-operated
chaperone sigma-1 receptors in the treatment of neuropsychiatric
disorders. Expert Opin Ther Targets 2011, 15:557–577.
8. Maurice T, Su TP: The pharmacology of sigma-1 receptors. Pharmacol Ther
2009, 124:195–206.
9. Tagashira H, Zhang C, Lu YM, Hasegawa H, Kanai H, Han F, Fukunaga K:
Stimulation of sigma(1)-receptor restores abnormal mitochondrial Ca(2+)
mobilization and ATP production following cardiac hypertrophy.
Biochim Biophys Acta 1830, 2013:3082–3094.
10. Megalizzi V, Le Mercier M, Decaestecker C: Sigma receptors and their
ligands in cancer biology: overview and new perspectives for cancer
therapy. Med Res Rev 2012, 32:410–427.
11. Hayashi T, Justinova Z, Hayashi E, Cormaci G, Mori T, Tsai SY, Barnes C,
Goldberg SR, Su TP: Regulation of sigma-1 receptors and endoplasmic
reticulum chaperones in the brain of methamphetamine self-
administering rats. J Pharmacol Exp Ther 2010, 332:1054–1063.
12. Hiranita T, Soto PL, Tanda G, Katz JL: Reinforcing effects of sigma-receptor
agonists in rats trained to self-administer cocaine. J Pharmacol Exp Ther
2010, 332:515–524.
13. Villard V, Espallergues J, Keller E, Alkam T, Nitta A, Yamada K, Nabeshima T,
Vamvakides A, Maurice T: Antiamnesic and neuroprotective effects of the
aminotetrahydrofuran derivative ANAVEX1-41 against amyloid beta(25-
35)-induced toxicity in mice. Neuropsychopharmacology 2009,
34:1552–1566.
14. Yao H, Yang Y, Kim KJ, Bethel-Brown C, Gong N, Funa K, Gendelman HE, Su
TP, Wang JQ, Buch S: Molecular mechanisms involving sigma receptor-
mediated induction of MCP-1: implication for increased monocyte
transmigration. Blood 2010, 115:4951–4962.
15. Ajmo CT Jr, Vernon DO, Collier L, Pennypacker KR, Cuevas J: Sigma receptor
activation reduces infarct size at 24 hours after permanent middle
cerebral artery occlusion in rats. Curr Neurovasc Res 2006, 3:89–98.
16. Cuevas J, Behensky A, Deng W, Katnik C: Afobazole modulates neuronal
response to ischemia and acidosis via activation of sigma-1 receptors.
J Pharmacol Exp Ther 2011, 339:152–160.
17. Tseng LF, Hogan QH, Wu HE: (+)-Morphine attenuates the
(-)-morphine-produced tail-flick inhibition via the sigma-1 receptor in
the mouse spinal cord. Life Sci 2011, 89:875–877.
18. Terashvili M, Wu HE, Moore RM, Harder DR, Tseng LF: (+)-Morphine
and (-)-morphine stereoselectively attenuate the (-)-morphine-
produced tail-flick inhibition via the naloxone-sensitive sigma
receptor in the ventral periaqueductal gray of the rat. Eur J
Pharmacol 2007, 571:1–7.
19. Wu HE, Hong JS, Tseng LF: Stereoselective action of (+)-morphine over
(-)-morphine in attenuating the (-)-morphine-produced antinociception
via the naloxone-sensitive sigma receptor in the mouse. Eur J Pharmacol
2007, 571:145–151.
Bangaru et al. Molecular Pain 2013, 9:47 Page 12 of 13
http://www.molecularpain.com/content/9/1/4720. Chien CC, Pasternak GW: Selective antagonism of opioid analgesia by a
sigma system. J Pharmacol Exp Ther 1994, 271:1583–1590.
21. Chien CC, Pasternak GW: Sigma antagonists potentiate opioid analgesia
in rats. Neurosci Lett 1995, 190:137–139.
22. Mei J, Pasternak GW: Sigma1 receptor modulation of opioid analgesia in
the mouse. J Pharmacol Exp Ther 2002, 300:1070–1074.
23. Mei J, Pasternak GW: Modulation of brainstem opiate analgesia in the rat
by sigma 1 receptors: a microinjection study. J Pharmacol Exp Ther 2007,
322:1278–1285.
24. Kim HW, Kwon YB, Roh DH, Yoon SY, Han HJ, Kim KW, Beitz AJ, Lee JH:
Intrathecal treatment with sigma1 receptor antagonists reduces
formalin-induced phosphorylation of NMDA receptor subunit 1 and the
second phase of formalin test in mice. Br J Pharmacol 2006, 148:490–498.
25. Roh DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Kim KW, Han HJ, Beitz AJ, Na
HS, Lee JH: Intrathecal injection of the sigma(1) receptor antagonist
BD1047 blocks both mechanical allodynia and increases in spinal NR1
expression during the induction phase of rodent neuropathic pain.
Anesthesiology 2008, 109:879–889.
26. Romero L, Zamanillo D, Nadal X, Sanchez-Arroyos R, Rivera-Arconada I,
Dordal A, Montero A, Muro A, Bura A, Segales C, et al: Pharmacological
properties of S1RA, a new sigma-1 receptor antagonist that inhibits
neuropathic pain and activity-induced spinal sensitization. Br J Pharmacol
2012, 166:2289–2306.
27. Roh DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Kim KW, Han HJ, Beitz AJ, Lee
JH: Intrathecal administration of sigma-1 receptor agonists facilitates
nociception: Involvement of a protein kinase C-dependent pathway.
J Neurosci Res 2008, 86:3644–3654.
28. Roh DH, Choi SR, Yoon SY, Kang SY, Moon JY, Kwon SG, Han HJ, Beitz AJ,
Lee JH: Spinal nNOS activation mediates sigma-1 receptor-induced
mechanical and thermal hypersensitivity in mice: involvement of PKC-
dependent NR1 phosphorylation. Br J Pharmacol 2011, 163:1707–1720.
29. Yoon SY, Roh DH, Seo HS, Kang SY, Han HJ, Beitz AJ, Lee JH: Intrathecal
injection of the neurosteroid, DHEAS, produces mechanical allodynia in
mice: involvement of spinal sigma-1 and GABA receptors. Br J Pharmacol
2009, 157:666–673.
30. Zimmermann M: Pathobiology of neuropathic pain. Eur J Pharmacol 2001,
429:23–37.
31. von Hehn CA, Baron R, Woolf CJ: Deconstructing the neuropathic pain
phenotype to reveal neural mechanisms. Neuron 2012, 73:638–652.
32. Cai YQ, Chen SR, Pan HL: Upregulation of nuclear factor of activated T-
cells by nerve injury contributes to development of neuropathic pain.
J Pharmacol Exp Ther 2013, 345:161–168.
33. Inquimbert P, Bartels K, Babaniyi OB, Barrett LB, Tegeder I, Scholz J:
Peripheral nerve injury produces a sustained shift in the balance
between glutamate release and uptake in the dorsal horn of the spinal
cord. Pain 2012, 153:2422–2431.
34. Takeuchi Y, Yamasaki M, Nagumo Y, Imoto K, Watanabe M, Miyata M:
Rewiring of afferent fibers in the somatosensory thalamus of mice
caused by peripheral sensory nerve transection. J Neurosci 2012,
32:6917–6930.
35. Rigaud M, Gemes G, Weyker PD, Cruikshank JM, Kawano T, Wu HE, Hogan
QH: Axotomy depletes intracellular calcium stores in primary sensory
neurons. Anesthesiology 2009, 111:381–392.
36. Hogan QH, McCallum JB, Sarantopoulos C, Aason M, Mynlieff M, Kwok WM,
Bosnjak ZJ: Painful neuropathy decreases membrane calcium current in
mammalian primary afferent neurons. Pain 2000, 86:43–53.
37. McCallum JB, Kwok WM, Sapunar D, Fuchs A, Hogan QH: Painful peripheral
nerve injury decreases calcium current in axotomized sensory neurons.
Anesthesiology 2006, 105:160–168.
38. Hayashi T, Maurice T, Su TP: Ca(2+) signaling via sigma(1)-receptors: novel
regulatory mechanism affecting intracellular Ca(2+) concentration.
J Pharmacol Exp Ther 2000, 293:788–798.
39. Zhang H, Cuevas J: Sigma receptors inhibit high-voltage-activated
calcium channels in rat sympathetic and parasympathetic neurons.
J Neurophysiol 2002, 87:2867–2879.
40. Hayashi T, Su TP: Sigma-1 receptor ligands: potential in the treatment of
neuropsychiatric disorders. CNS Drugs 2004, 18:269–284.
41. Maurice T, Gregoire C, Espallergues J: Neuro(active)steroids actions at the
neuromodulatory sigma1 (sigma1) receptor: biochemical and
physiological evidences, consequences in neuroprotection.
Pharmacol Biochem Behav 2006, 84:581–597.42. Schaeffer V, Meyer L, Patte-Mensah C, Eckert A, Mensah-Nyagan AG: Sciatic
nerve injury induces apoptosis of dorsal root ganglion satellite glial cells
and selectively modifies neurosteroidogenesis in sensory neurons.
Glia 2010, 58:169–180.
43. Hayashi T, Su TP: Regulating ankyrin dynamics: Roles of sigma-1
receptors. Proc Natl Acad Sci USA 2001, 98:491–496.
44. Weick M, Cherkas PS, Hartig W, Pannicke T, Uckermann O, Bringmann A, Tal M,
Reichenbach A, Hanani M: P2 receptors in satellite glial cells in trigeminal
ganglia of mice. Neuroscience 2003, 120:969–977.
45. Gemes G, Bangaru ML, Wu HE, Tang Q, Weihrauch D, Koopmeiners AS,
Cruikshank JM, Kwok WM, Hogan QH: Store-operated Ca2+ entry in
sensory neurons: functional role and the effect of painful nerve injury.
J Neurosci 2011, 31:3536–3549.
46. Hanani M: Satellite glial cells in sensory ganglia: from form to function.
Brain Res Brain Res Rev 2005, 48:457–476.
47. Hayashi T, Su TP: Sigma-1 receptors at galactosylceramide-enriched lipid
microdomains regulate oligodendrocyte differentiation. Proc Natl Acad
Sci USA 2004, 101:14949–14954.
48. Xing J, Lu J, Li J: Acid-sensing ion channel subtype 3 function and
immunolabelling increases in skeletal muscle sensory neurons following
femoral artery occlusion. J Physiol 2012, 590:1261–1272.
49. Zoga V, Kawano T, Liang MY, Bienengraeber M, Weihrauch D, McCallum B,
Gemes G, Hogan Q, Sarantopoulos C: KATP channel subunits in rat dorsal
root ganglia: alterations by painful axotomy. Mol Pain 2010, 6:6.
50. Monnet FP, Debonnel G, Junien JL, De Montigny C: N-methyl-D-aspartate-
induced neuronal activation is selectively modulated by sigma
receptors. Eur J Pharmacol 1990, 179:441–445.
51. Son JS, Kwon YB: Sigma-1 Receptor Antagonist BD1047 Reduces
Allodynia and Spinal ERK Phosphorylation Following Chronic
Compression of Dorsal Root Ganglion in Rats. Korean J Physiol Pharmacol
2010, 14:359–364.
52. Hammond DL, Ackerman L, Holdsworth R, Elzey B: Effects of spinal nerve
ligation on immunohistochemically identified neurons in the L4 and L5
dorsal root ganglia of the rat. J Comp Neurol 2004, 475:575–589.
53. Aanonsen LM, Seybold VS: Phencyclidine and sigma receptors in rat
spinal cord: binding characterization and quantitative autoradiography.
Synapse 1989, 4:1–10.
54. McCann DJ, Su TP: Haloperidol competitively inhibits the binding of
(+)-[3H]SKF-10,047 to sigma sites. Eur J Pharmacol 1990, 180:361–364.
55. Gundlach AL, Largent BL, Snyder SH: Autoradiographic localization of
sigma receptor binding sites in guinea pig and rat central nervous
system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J Neurosci
1986, 6:1757–1770.
56. Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE: The sigma-1 receptor
chaperone as an inter-organelle signaling modulator. Trends Pharmacol
Sci 2010, 31:557–566.
57. Kourrich S, Su TP, Fujimoto M, Bonci A: The sigma-1 receptor: roles in
neuronal plasticity and disease. Trends Neurosci 2012, 35:762–771.
58. Fukuoka T, Tokunaga A, Kondo E, Miki K, Tachibana T, Noguchi K: Change in
mRNAs for neuropeptides and the GABA(A) receptor in dorsal root ganglion
neurons in a rat experimental neuropathic pain model. Pain 1998, 78:13–26.
59. Fukuoka T, Tokunaga A, Kondo E, Noguchi K: The role of neighboring
intact dorsal root ganglion neurons in a rat neuropathic pain model. In
Proceedings of the 9th world congress on pain. 1st edition. Edited by Dever
M, Rowbotham MC, Weisenfeld-Hallin Z. Seattle, WA: IASP Press;
2000:137–146.
60. Murinson BB, Griffin JW: C-fiber structure varies with location in
peripheral nerve. J Neuropathol Exp Neurol 2004, 63:246–254.
61. Wu G, Ringkamp M, Hartke TV, Murinson BB, Campbell JN, Griffin JW, Meyer
RA: Early onset of spontaneous activity in uninjured C-fiber nociceptors
after injury to neighboring nerve fibers. J Neurosci 2001, 21:RC140.
62. Ossipov MH, Porreca F: Neuropathic pain: basic mechansim (animal).
In Science of Pain. firstth edition Edited by Basbaum AI, Bushnell MC.
Oxford, UK: Elsevier; 2009:833–855.
63. Cendan CM, Pujalte JM, Portillo-Salido E, Montoliu L, Baeyens JM: Formalin-
induced pain is reduced in sigma(1) receptor knockout mice.
Eur J Pharmacol 2005, 511:73–74.
64. Entrena JM, Cobos EJ, Nieto FR, Cendan CM, Gris G, Del Pozo E, Zamanillo
D, Baeyens JM: Sigma-1 receptors are essential for capsaicin-induced
mechanical hypersensitivity: studies with selective sigma-1 ligands and
sigma-1 knockout mice. Pain 2009, 143:252–261.
Bangaru et al. Molecular Pain 2013, 9:47 Page 13 of 13
http://www.molecularpain.com/content/9/1/4765. de la Puente B, Nadal X, Portillo-Salido E, Sanchez-Arroyos R, Ovalle S,
Palacios G, Muro A, Romero L, Entrena JM, Baeyens JM, et al: Sigma-1
receptors regulate activity-induced spinal sensitization and neuropathic
pain after peripheral nerve injury. Pain 2009, 145:294–303.
66. Kibaly C, Meyer L, Patte-Mensah C, Mensah-Nyagan AG: Biochemical and
functional evidence for the control of pain mechanisms by
dehydroepiandrosterone endogenously synthesized in the spinal cord.
Faseb J 2008, 22:93–104.
67. Penas C, Pascual-Font A, Mancuso R, Fores J, Casas C, Navarro X: Sigma
receptor agonist 2-(4-morpholinethyl)1 phenylcyclohexanecarboxylate
(Pre084) increases GDNF and BiP expression and promotes
neuroprotection after root avulsion injury. J Neurotrauma 2011,
28:831–840.
68. Ruscher K, Shamloo M, Rickhag M, Ladunga I, Soriano L, Gisselsson L,
Toresson H, Ruslim-Litrus L, Oksenberg D, Urfer R, et al: The sigma-1
receptor enhances brain plasticity and functional recovery after
experimental stroke. Brain 2011, 134:732–746.
69. Hall AK, Landis SC: Division and migration of satellite glia in the
embryonic rat superior cervical ganglion. J Neurocytol 1992, 21:635–647.
70. Shen YC, Wang YH, Chou YC, Liou KT, Yen JC, Wang WY, Liao JF:
Dimemorfan protects rats against ischemic stroke through activation of
sigma-1 receptor-mediated mechanisms by decreasing glutamate
accumulation. J Neurochem 2008, 104:558–572.
71. Behensky AA, Cortes-Salva M, Seminerio MJ, Matsumoto RR, Antilla JC,
Cuevas J: In vitro evaluation of guanidine analogs as sigma receptor
ligands for potential anti-stroke therapeutics. J Pharmacol Exp Ther 2013,
344:155–166.
72. Moon JY, Roh DH, Yoon SY, Kang SY, Choi SR, Kwon SG, Choi HS, Han HJ,
Beitz AJ, Lee JH: Sigma-1 receptor-mediated increase in spinal p38 MAPK
phosphorylation leads to the induction of mechanical allodynia in mice
and neuropathic rats. Exp Neurol 2013, 247:383–391.
73. Kim SH, Chung JM: An experimental model for peripheral neuropathy
produced by segmental spinal nerve ligation in the rat. Pain 1992,
50:355–363.
74. Hogan Q, Sapunar D, Modric-Jednacak K, McCallum JB: Detection of
neuropathic pain in a rat model of peripheral nerve injury.
Anesthesiology 2004, 101:476–487.
75. Wu HE, Gemes G, Zoga V, Kawano T, Hogan QH: Learned avoidance from
noxious mechanical simulation but not threshold semmes weinstein
filament stimulation after nerve injury in rats. J Pain 2010, 11:280–286.
76. Bangaru ML, Park F, Hudmon A, McCallum JB, Hogan QH: Quantification of
gene expression after painful nerve injury: validation of optimal
reference genes. J Mol Neurosci 2012, 46:497–504.
77. Hayashi T, Lewis A, Hayashi E, Betenbaugh MJ, Su TP: Antigen retrieval to
improve the immunocytochemistry detection of sigma-1 receptors and
ER chaperones. Histochem Cell Biol 2011, 135:627–637.
78. Stemkowski PL, Smith PA: Long-term IL-1beta exposure causes
subpopulation-dependent alterations in rat dorsal root ganglion neuron
excitability. J Neurophysiol 2012, 107:1586–1597.
79. Obata K, Katsura H, Mizushima T, Sakurai J, Kobayashi K, Yamanaka H, Dai Y,
Fukuoka T, Noguchi K: Roles of extracellular signal-regulated protein
kinases 5 in spinal microglia and primary sensory neurons for
neuropathic pain. J Neurochem 2007, 102:1569–1584.
doi:10.1186/1744-8069-9-47
Cite this article as: Bangaru et al.: Sigma-1 receptor expression in
sensory neurons and the effect of painful peripheral nerve injury.
Molecular Pain 2013 9:47.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
